Cancer vaccine - AVI BioPharma

Drug Profile

Cancer vaccine - AVI BioPharma

Alternative Names: AVICINE; CTP 37

Latest Information Update: 15 Jan 2007

Price : $50

At a glance

  • Originator AVI BioPharma
  • Class Cancer vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Colorectal cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 07 Mar 2005 Avicine® is still available for partnering (http://www.avibio.com)
  • 08 Sep 2003 No development reported - Phase-I for Prostate cancer in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top